Chemical Compound Review:
paraxanthine 1,7-dimethyl-3H-purine-2,6- dione
Synonyms:
p-Xanthine, Lopac-D-5385, CHEMBL1158, PubChem23157, SureCN232702, ...
Grosso,
Triche,
Belanger,
Benowitz,
Holford,
Bracken,
Geraets,
Moonen,
Wouters,
Bast,
Hageman,
Nowell,
Sweeney,
Hammons,
Kadlubar,
Lang,
Casley,
Menzies,
Whitehouse,
Moon,
Becquemont,
Chazouilleres,
Serfaty,
Poirier,
Broly,
Jaillon,
Poupon,
Funck-Brentano,
Hawke,
Allen,
Lindinger,
Horrigan,
Kelly,
Connor,
- Maternal serum paraxanthine, a caffeine metabolite, and the risk of spontaneous abortion. Klebanoff, M.A., Levine, R.J., DerSimonian, R., Clemens, J.D., Wilkins, D.G. N. Engl. J. Med. (1999)
- The effect of liver disease on urine caffeine metabolite ratios. Denaro, C.P., Wilson, M., Jacob, P., Benowitz, N.L. Clin. Pharmacol. Ther. (1996)
- Caffeine metabolites in umbilical cord blood, cytochrome P-450 1A2 activity, and intrauterine growth restriction. Grosso, L.M., Triche, E.W., Belanger, K., Benowitz, N.L., Holford, T.R., Bracken, M.B. Am. J. Epidemiol. (2006)
- Methylxanthines: toxicity to humans. 3. Theobromine, paraxanthine and the combined effects of methylxanthines. Stavric, B. Food Chem. Toxicol. (1988)
- The pharmacokinetics of caffeine in Nigerian children suffering from malaria and kwashiorkor. Akinyinka, O.O., Sowunmi, A., Honeywell, R., Renwick, A.G. Eur. J. Clin. Pharmacol. (2000)
- Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Faber, M.S., Fuhr, U. Clin. Pharmacol. Ther. (2004)
- Postsynaptic dopamine/adenosine interaction: II. Postsynaptic dopamine agonism and adenosine antagonism of methylxanthines in short-term reserpinized mice. Ferré, S., Herrera-Marschitz, M., Grabowska-Andén, M., Casas, M., Ungerstedt, U., Andén, N.E. Eur. J. Pharmacol. (1991)
- Immunomodulatory effects of caffeine: friend or foe? Horrigan, L.A., Kelly, J.P., Connor, T.J. Pharmacol. Ther. (2006)
- Sympathomimetic effects of paraxanthine and caffeine in humans. Benowitz, N.L., Jacob, P., Mayan, H., Denaro, C. Clin. Pharmacol. Ther. (1995)
- Caffeine disposition after oral doses. Bonati, M., Latini, R., Galletti, F., Young, J.F., Tognoni, G., Garattini, S. Clin. Pharmacol. Ther. (1982)
- Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Rostami-Hodjegan, A., Nurminen, S., Jackson, P.R., Tucker, G.T. Pharmacogenetics (1996)
- Synthesis of paraxanthine analogs (1,7-disubstituted xanthines) and other xanthines unsubstituted at the 3-position: structure-activity relationships at adenosine receptors. Müller, C.E., Shi, D., Manning, M., Daly, J.W. J. Med. Chem. (1993)
- Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2. Labedzki, A., Buters, J., Jabrane, W., Fuhr, U. Biochem. Pharmacol. (2002)
- Analysis of within-subject variation of caffeine metabolism when used to determine cytochrome P4501A2 and N-acetyltransferase-2 activities. McQuilkin, S.H., Nierenberg, D.W., Bresnick, E. Cancer Epidemiol. Biomarkers Prev. (1995)
- Disposition of caffeine and its metabolites in man. Tang-Liu, D.D., Williams, R.L., Riegelman, S. J. Pharmacol. Exp. Ther. (1983)
- Caffeine metabolites are inhibitors of the nuclear enzyme poly(ADP-ribose)polymerase-1 at physiological concentrations. Geraets, L., Moonen, H.J., Wouters, E.F., Bast, A., Hageman, G.J. Biochem. Pharmacol. (2006)
- Paraxanthine, a caffeine metabolite, dose dependently increases [Ca(2+)](i) in skeletal muscle. Hawke, T.J., Allen, D.G., Lindinger, M.I. J. Appl. Physiol. (2000)
- Paraxanthine displaces the binding of [3H]SCH 23390 from rat striatal membranes. Ferré, S., Guix, T., Sallés, J., Badia, A., Parra, P., Jané, F., Herrera-Marschitz, M., Ungerstedt, U., Casas, M. Eur. J. Pharmacol. (1990)
- Override of the radiation-induced mitotic block in human tumour cells by methylxanthines and its relationship to the potentiation of cytotoxicity. Musk, S.R., Steel, G.G. Int. J. Radiat. Biol. (1990)
- Four-week treatment with omeprazole increases the metabolism of caffeine. Nousbaum, J.B., Berthou, F., Carlhant, D., Riche, C., Robaszkiewicz, M., Gouerou, H. Am. J. Gastroenterol. (1994)
- Determination of theophylline in serum and saliva in the presence of caffeine and its metabolites. Moncrieff, J. J. Chromatogr. (1991)
- Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Sachse, C., Brockmöller, J., Bauer, S., Roots, I. British journal of clinical pharmacology. (1999)
- In vivo effect of clarithromycin on multiple cytochrome P450s. Bruce, M.A., Hall, S.D., Haehner-Daniels, B.D., Gorski, J.C. Drug Metab. Dispos. (2001)
- Effect of interferon alpha-ribavirin bitherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransferase-2 activities in patients with chronic active hepatitis C. Becquemont, L., Chazouilleres, O., Serfaty, L., Poirier, J.M., Broly, F., Jaillon, P., Poupon, R., Funck-Brentano, C. Clin. Pharmacol. Ther. (2002)
- CYP2A6 activity determined by caffeine phenotyping: association with colorectal cancer risk. Nowell, S., Sweeney, C., Hammons, G., Kadlubar, F.F., Lang, N.P. Cancer Epidemiol. Biomarkers Prev. (2002)
- Detection of quantitative trait loci affecting caffeine metabolism by interval mapping in a genome-wide scan of C3H/HeJ x APN F(2) mice. Casley, W.L., Menzies, J.A., Whitehouse, L.W., Moon, T.W. Drug Metab. Dispos. (1999)
- Caffeine, estradiol, and progesterone interact with human CYP1A1 and CYP1A2. Evidence from cDNA-directed expression in Saccharomyces cerevisiae. Eugster, H.P., Probst, M., Würgler, F.E., Sengstag, C. Drug Metab. Dispos. (1993)
- Orientation of caffeine within the active site of human cytochrome P450 1A2 based on NMR longitudinal (T1) relaxation measurements. Regal, K.A., Nelson, S.D. Arch. Biochem. Biophys. (2000)
- Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Fuhr, U., Rost, K.L. Pharmacogenetics (1994)
- Evaluation of chromatographic and kit immunoassay techniques for the measurement of theophylline in serum: a study based on external quality assurance measurements. Wilson, J.F., Williams, J., Tsanaclis, L.M., Tedstone, J.E., Richens, A. Therapeutic drug monitoring. (1988)
- K+ transport in resting rat hind-limb skeletal muscle in response to paraxanthine, a caffeine metabolite. Hawke, T.J., Willmets, R.G., Lindinger, M.I. Can. J. Physiol. Pharmacol. (1999)
- Caffeine and its dimethylxanthine metabolites in two cases of caffeine overdose: a cause of falsely elevated theophylline concentrations in serum. Fligner, C.L., Opheim, K.E. Journal of analytical toxicology. (1988)
- Development of a biosensor for caffeine. Babu, V.R., Patra, S., Karanth, N.G., Kumar, M.A., Thakur, M.S. Anal. Chim. Acta (2007)